Dublin, Jan. 26, 2017 -- Research and Markets has announced the addition of the "Implantable Infusion Pumps Market Analysis & Trends- Application (Cancer Treatment, Cancer Pain, Noncancer Pain, Spasticity, Analgesia, Mixed Sarcoma and Skin Cancers, Gastric Cancer and Diabetes Mellitus) - Forecast to 2025" report to their offering.
The Global Implantable Infusion Pumps Market is poised to grow at a CAGR of around 6.3% over the next decade to reach approximately $14.33 billion by 2025.
Some of the prominent trends that the market is Chemotherapy for cancer patients, Surge for near-physiologic programmable method of insulin delivery, Increase in device based drug delivery technologies and Growth Opportunities/Investment Opportunities.
Based on Application the market is categorized into Cancer Treatment, Spasticity, Analgesia and Diabetes Mellitus. The Cancer Treatment segment is further divided as Cancer Pain, Noncancer Pain, Mixed Sarcoma and Skin Cancers and Gastric Cancer.
This industry report analyzes the global markets for Implantable Infusion Pumps across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025.
The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
Key Topics Covered:
1 Market Outline
2 Executive Summary
3 Market Overview
3.1 Current Trends
3.1.1 Chemotherapy for cancer patients
3.1.2 Surge for near-physiologic programmable method of insulin delivery
3.1.3 Increase in device based drug delivery technologies
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness
4 Implantable Infusion Pumps Market, By Application
4.1 Cancer Treatment
4.1.1.1 Cancer Pain
4.1.1.2 Noncancer Pain
4.1.1.3 Mixed Sarcoma and Skin Cancers
4.1.1.4 Gastric Cancer
4.2 Spasticity
4.3 Analgesia
4.4 Diabetes Mellitus
5 Implantable Infusion Pumps Market, By Geography
6 Key Player Activities
6.1 Acquisitions & Mergers
6.2 Agreements, Partnerships, Collaborations and Joint Ventures
6.3 Product Launch & Expansions
6.4 Other Activities
7 Leading Companies
7.1 Alnylam Pharmaceuticals, Inc.
7.2 Debiotech S.A.
7.3 Delpor, Inc.
7.4 Eksigent Technologies, LLC
7.5 Eli Lilly and Company
7.6 Flowonix Medical, Inc.
7.7 FluidSynchrony, LLC
7.8 Intarcia Therapeutics, Inc.
7.9 Medallion Therapeutics, Inc.
7.10 Nano Precision Medical
7.11 Pharmaco-Kinesis Corporation
7.12 University of Southern California Company
7.13 Halyard Health
7.14 Codman & Shurtleff
For more information about this report visit http://www.researchandmarkets.com/research/sm2s9p/implantable
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infusions and Injectables , Needles and Syringes , Endocrinology , Dermatological Drugs


Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 



